Given the promising results of this trial, the FDA approved ide-cel in March 2021 for patients with R/R MM who have failed at least four prior lines of therapy [6], including a proteasome inhibitor (PI), immunomodulatory drug (IMID), and anti-CD38 monoclonal antibody (mAb). This evidence concerns the gene CD38 and Miyoshi myopathy.